CTRI/2023/06/054229尚未招募Unknown
A Case control study to compare prevalence of liverfibrosis in patients with Acanthosis Nigricans and without Acanthosis Nigricans.
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- A
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Patients with T2DM (up to 15 years Duration)
- •2. Age 25 to 60 years
- •3. BMI >25 kg/m² to >40 kg/m²
- •4. Gender- Both (Male & Female)
- •5. Mild, Moderate and Severe acanthosis nigricans (Photograph)
排除标准
- •1. Chronic Alcoholic with Moderate to Severe.
- •2. BMI >40 kg/m²
- •3. Congestive heart disease
- •4. Positive hepatitis B or hepatitis C, secondary causes of fatty liver (eg. consumption of
- •amiodarone and tamoxifen) and congestive hepatopathy.
- •5. Severe end organ damage or chronic diseases: renal/hepatic failure, any malignancy,
- •major systemic illness etc.
研究者
相似试验
已完成
不适用
Paraoxonase 1 (PON-1) polymorphisms,activity and Coronary Artery Disease (CAD)CTRI/2017/08/009319Diamond Jubilee Society Trust King Edward Memorial Hospital602
招募中
不适用
A comparative study looking at the prevalence of human papilloma virus (HPV) and HPV types in term and preterm labour cases by testing placentae, high vaginal swabs and maternal blood (cfDNA) (HIPPOP trial).Preterm labour (PTL)Premature preterm rupture of membranes (PPROM)Human Papilloma Virus (HPV)ACTRN12618000266268niversity of Otago200
已完成
3 期
A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197, LATITUDE STUDY) (Short title: LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE (LATITUDE)-TIMI 60)acute coronary syndromeheart attack10011082NL-OMON41191GlaxoSmithKline870
进行中（未招募）
1 期
PM1116197 is a Clinical Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to PlaceboEUCTR2013-000657-50-GBGlaxoSmithKline Research & Development Ltd25,500
进行中（未招募）
1 期
PM1116197 is a Clinical Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to PlaceboSubjects with ACS on the time to first occurrence of adjudicated MACE (defined as CV death, MI, or severe recurrent ischemia [SRI-UR])MedDRA version: 17.1Level: LLTClassification code 10003723Term: Attack coronarySystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 17.1Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 17.1Level: LLTClassification code 10071111Term: Non ST segment elevation acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 17.1Level: LLTClassification code 10041894Term: ST segment elevationSystem Organ Class: 100000004848EUCTR2013-000657-50-BGGlaxoSmithKline Research & Development Ltd25,500